Published in Pharmacogenetics on August 01, 1998
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Individual response to treatment: is it a valid assumption? BMJ (2004) 1.32
SNPs in cancer research and treatment. Br J Cancer (2004) 1.16
A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS (2010) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol (2014) 0.92
The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet (2014) 0.90
Biomarkers for ischemic preconditioning: finding the responders. J Cereb Blood Flow Metab (2014) 0.85
Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn (2007) 0.85
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. J Zhejiang Univ Sci B (2012) 0.85
Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis (2015) 0.84
ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med (2012) 0.84
Biomarkers for stroke. J Stroke (2013) 0.83
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics (2013) 0.83
Genetics of inflammatory bowel disease: current status and future directions. Can J Gastroenterol (2006) 0.82
Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med (2012) 0.82
Pharmacogenomics--how close/far are we to practising individualized medicine for children? Br J Clin Pharmacol (2015) 0.82
Role of Statistical Random-Effects Linear Models in Personalized Medicine. Curr Pharmacogenomics Person Med (2012) 0.81
Mastering variation: variance components and personalised medicine. Stat Med (2015) 0.81
Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases. Pharmacogenet Genomics (2016) 0.80
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res (2015) 0.79
Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2013) 0.79
Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. Br J Clin Pharmacol (1999) 0.78
Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood. Oncol Lett (2016) 0.78
Personalized therapy for pancreatic cancer: Myth or reality in 2010? J Gastrointest Oncol (2010) 0.77
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. Clin Transl Sci (2016) 0.77
Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol (2009) 0.77
Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. Indian J Nephrol (2010) 0.77
Concept-based learning of personalized prescribing. Br J Clin Pharmacol (2012) 0.76
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics (2016) 0.76
Bone mass pharmacogenetics and ethnic health implications. Clin Cases Miner Bone Metab (2007) 0.76
Impact of germline and somatic missense variations on drug binding sites. Pharmacogenomics J (2016) 0.75
Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med (2016) 0.75
Pharmacogenetics and the development of personalized approaches for combination therapy in asthma. Curr Allergy Asthma Rep (2013) 0.75
Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. Med Sci Monit (2015) 0.75
Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers Med (2015) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS (2016) 0.75
Understanding Variation in Sets of N-of-1 Trials. PLoS One (2016) 0.75
Individualization of antiretroviral therapy - Pharmacogenomic aspect. Indian J Med Res (2015) 0.75
GENETIC VARIATION IN THE β(2)-ADRENERGIC RECEPTOR: IMPACT ON INTERMEDIATE CARDIOVASCULAR PHENOTYPES. Curr Pharmacogenomics Person Med (2008) 0.75
Testing gene-treatment interactions in pharmacogenetic studies. J Biopharm Stat (2010) 0.75
Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray. Int J Clin Exp Med (2015) 0.75
In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane. Pharmacol Res Perspect (2017) 0.75
Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. Heart Fail Rev (2010) 0.75
Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics (1992) 2.21
A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol (1984) 1.99
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics (2000) 1.94
Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med (1986) 1.76
Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther (1991) 1.76
Variability in caffeine metabolism. Clin Pharmacol Ther (1983) 1.74
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther (1991) 1.55
The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther (1993) 1.51
Correspondence re: S. H. McQuilkin et al., analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-Acetyltransferase-2 activities. Cancer Epidemiol., Biomarkers & Prev., 4: 139-146, 1995. Cancer Epidemiol Biomarkers Prev (1996) 1.41
Secondary metrics for the assessment of bioequivalence. J Pharm Sci (1997) 1.39
Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics (1992) 1.31
Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther (1983) 1.28
Fitting of enzyme kinetic data without prior knowledge of weights. Biochem J (1981) 1.19
Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17
Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther (1991) 1.13
The value of decompression for acute experimental spinal cord compression injury. J Neurosurg (1980) 1.11
Decompression of the spinal cord improves recovery after acute experimental spinal cord compression injury. Paraplegia (1987) 1.10
Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone. Clin Pharmacol Ther (1973) 1.09
Evaluation of the bioequivalence of highly-variable drugs and drug products. Pharm Res (2001) 1.08
Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci (1977) 1.03
Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol (1980) 1.02
Aversive conditioning by psychoactive drugs: effects of morphine, alcohol and chlordiazepoxide. Psychopharmacologia (1973) 0.98
The science of pharmacological variability: an essay. Clin Pharmacol Ther (1999) 0.98
Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol (1986) 0.97
Effects of verapamil on [3H]norepinephrine release. J Cardiovasc Pharmacol (1985) 0.96
Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem Pharmacol (1998) 0.93
Interpretation of nonhyperbolic behavior in enzymic systems. II. Quantitative characteristics of rate and binding functions. Can J Biochem (1971) 0.93
Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab Dispos (1983) 0.93
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology (1999) 0.91
Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children. Drug Metab Rev (1983) 0.90
Design of experiments for the precise estimation of dose-response parameters: the Hill equation. J Theor Biol (1986) 0.89
A method for studying drug metabolism in populations: racial differences in amobarbital metabolism. Clin Pharmacol Ther (1979) 0.89
Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics (1996) 0.88
Metabolic fate of phenobarbital in man. N-Glucoside formation. Drug Metab Dispos (1980) 0.88
Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. Biochem Pharmacol (1987) 0.88
Evaluation of Hill slopes and Hill coefficients when the saturation binding or velocity is not known. Eur J Biochem (1975) 0.86
Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J (1980) 0.86
A statistical comparison of parameter estimation for the Michaelis-Menten kinetics of human placental hexosaminidase. Can J Biochem Cell Biol (1985) 0.86
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J Clin Psychopharmacol (2001) 0.85
Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can Anaesth Soc J (1976) 0.84
Amobarbital metabolism in man: N-glucoside formation. Res Commun Chem Pathol Pharmacol (1978) 0.84
The adenosine triphosphate (ATP) depletion test: comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility. Can Anaesth Soc J (1976) 0.84
Some problems of estimating macromolecule-ligand binding parameters. Acta Biol Med Ger (1973) 0.84
A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate. Drug Metab Dispos (1996) 0.83
Comparison of the caffeine skinned fibre tension (CSFT) test with the caffeine-halothane contracture (CHC) test in the diagnosis of malignant hyperthermia. Can Anaesth Soc J (1982) 0.83
Robust regression of enzyme kinetic data. Biochem J (1986) 0.83
Effect of pyrazole on ethanol metabolism in ethanol-tolerant rats. Can J Physiol Pharmacol (1975) 0.82
Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max). Int J Clin Pharmacol Ther (2003) 0.82
A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokinet Biopharm (1992) 0.82
Assessment of immediate post-anaesthetic recovery in young children following intravenous morphine infusions, halothane, and isoflurane. Can Anaesth Soc J (1984) 0.81
Optimal design of experiments for the estimation of precise hyperbolic kinetic and binding parameters. J Theor Biol (1981) 0.81
Genetic study of amobarbital elimination based on its kinetics in twins. Clin Pharmacol Ther (1976) 0.81
Sensitivity of empirical metrics of rate of absorption in bioequivalence studies. Pharm Res (2000) 0.81
Induction of P-450 in workers exposed to dioxin. Occup Environ Med (1995) 0.81
Interpretation of nonhyperbolic behavior in enzymic systems. I. Differentiation of model mechanisms. Can J Biochem (1971) 0.81
Adrenergic activity in arteries of spontaneously hypertensive rats. Can J Physiol Pharmacol (1981) 0.80
New linear plots for the separate estimation of Michaelis-Menten parameters. FEBS Lett (1974) 0.80
Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol (1997) 0.80
Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes. Eur J Clin Pharmacol (1997) 0.80
Erythro-Diols of wax from the uropygial gland of the turkey. J Lipid Res (1969) 0.79
Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics (1995) 0.79
The fate of phenobarbitone in children in hypothermia and at normal body temperature. Can Anaesth Soc J (1982) 0.79
Pharmacokinetics and bioavailability of pyrene in the rat. J Toxicol Environ Health (1991) 0.79
Porcine malignant hyperthermia: effects of halothane on mitochondrial respiration and calcium accumulation. Anesthesiology (1975) 0.79
Calcium uptake into muscle of pigs susceptible to malignant hyperthermia: in vitro and in vivo studies with and without halothane. Br J Anaesth (1975) 0.78
Effects of halothane and methoxyflurane on rat skeletal muscle mitochondria. Biochem Pharmacol (1972) 0.78
Distinctive patterns of amobarbital metabolites. Clin Pharmacol Ther (1978) 0.78
A urinary marker of alcohol intake. Cancer Epidemiol Biomarkers Prev (1995) 0.78
Without extrapolation, Cmax/AUC is an effective metric in investigations of bioequivalence. Pharm Res (1995) 0.78
Amobarbital--a probe of hepatic drug oxidation in man. Clin Pharmacol Ther (1976) 0.78
A simple test for acetylator phenotype using caffeine. 1984. Br J Clin Pharmacol (2004) 0.78
N-Glucosidation of amobarbital in the cat. Can J Physiol Pharmacol (1985) 0.77
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. Eur J Clin Pharmacol (2001) 0.77
Forskolin-resistant Y1 mutants harbor defects associated with the guanyl nucleotide-binding regulatory protein, Gs. J Biol Chem (1987) 0.77
Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence. J Biopharm Stat (1997) 0.77
Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle. Can Anaesth Soc J (1984) 0.76
A case of deficiency of N-hydroxylation of amobarbital. Clin Pharmacol Ther (1977) 0.76
(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics (1995) 0.76
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol (1998) 0.76
Effect of ethanol on the kinetics of rat brain (Na+ + K+) ATPase and K+-dependent phosphatase with different alkali ions. Biochem Pharmacol (1978) 0.76
Sequential metabolism of salicylamide exclusively to gentisamide 5-glucuronide and not gentisamide sulfate conjugates in single-pass in situ perfused rat liver. J Pharmacol Exp Ther (1990) 0.76
Effect of temperature, time and fascicle size on the caffeine contracture test. Can Anaesth Soc J (1980) 0.76
Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther (1995) 0.75
Relative bioavailability of commercial ampicillin formulations in man. Can Med Assoc J (1973) 0.75
Bioequivalence: tried and tested. Cardiovasc J Afr (2010) 0.75
Utilizing urinary metabolite data in studying the variability of acetaminophen metabolism. Pharmacogenetics (1993) 0.75
Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica (1998) 0.75
The effects of sympathetic denervation on spontaneous ventricular defibrillation in the rat. Can J Physiol Pharmacol (1992) 0.75
A method for the study of N-glucosidation in vitro--amobarbital-N-glucoside formation in incubations with human liver. Biochem Pharmacol (1980) 0.75
Pharmacokinetics of inhaled pyrene in rats. J Toxicol Environ Health (1994) 0.75
Percutaneous uptake, distribution, and excretion of pyrene in rats. J Toxicol Environ Health (1993) 0.75
Vasodepressor reaction induced by inferior vena caval occlusion and isoproterenol. Can J Physiol Pharmacol (1992) 0.75
Simultaneous determination of antipyrine, 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine in urine by gas chromatography chemical ionization mass spectrometry. Biomed Mass Spectrom (1982) 0.75
Species differences of amobarbital metabolism: dihydroxyamobarbital formation. Can J Physiol Pharmacol (1980) 0.75
An assessment of short-cut procedures for studying drug metabolism in vivo using amobarbital as a model drug. Eur J Clin Pharmacol (1982) 0.75
An enzyme-distributed system for lidocaine metabolism in the perfused rat liver preparation. J Pharmacokinet Biopharm (1986) 0.75